Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025

Talphera, Inc. (Nasdaq: TLPH), a San Mateo-based specialty pharmaceutical company that focuses on developing innovative therapies for medically supervised settings, has announced its plans for releasing its third quarter 2025 financial results. The results will be made available after market close on Wednesday, November 12, 2025. Following the release, the company will host a live webcast and conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its financial results and provide a corporate update.

Interested investors can access the webcast through the Investors section of Talphera's official website, where a slide presentation will accompany the discussion. Additionally, a replay of the webcast will be available on the website for 90 days after the event, providing ample opportunity for those unable to attend the live session to catch up on the details. For those wishing to join the conference call directly, a dedicated phone line is available for North American callers, and an alternative number for international participants, although toll charges may apply. The conference ID for participation is 08207.

Talphera’s lead product candidate, Niyad™, a lyophilized formulation of nafamostat, is under development as an anticoagulant for use in extracorporeal circuits and has garnered Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation highlights the innovative nature of Talphera's approach in addressing medical needs through advanced therapies. For deeper insights into the company's developments and future directions, interested parties are encouraged to visit their website at www.talphera.com.

As Talphera, Inc. (Nasdaq: TLPH) approaches its third quarter financial results and corporate update call on November 12, 2025, investors should prepare for potential volatility in the stock, driven by the anticipated financial disclosures and updates on its lead product candidate, Niyad™. The company has focused on the promising anticoagulant, which has garnered Breakthrough Device Designation from the FDA. This designation suggests that Niyad has the potential to significantly improve patient outcomes, positioning Talphera strategically within the specialty pharmaceuticals arena.

Given the current market backdrop, it will be important for investors to closely monitor key metrics in the upcoming earnings report. Specifically, revenue growth, R&D spending, and progress in clinical trials will be critical indicators of Talphera's operational health and future potential. A strong performance that demonstrates consistent progress could bolster investor confidence and lead to positive upward movement in stock prices.

Conversely, any unexpected delays in trial timelines or disappointing financial figures may trigger sell-offs. Thus, investors should be equipped to react based on the details revealed during the conference call, which typically covers not only the quarterly results but also insights into future strategies and developments.

Furthermore, access to the live webcast is recommended as it will provide real-time insights and allow investors to gauge management's tone and positioning. It may also be prudent to set stop-loss orders in anticipation of potential volatility following the earnings announcement.

In summary, while Talphera presents an intriguing opportunity due to its innovative approach and regulatory recognition, investors should weigh the risks carefully and remain vigilant as the date of the financial results approaches.